Potential Deleterious Effects of Vasopressin in Chronic Kidney Disease and Particularly Autosomal Dominant Polycystic Kidney Disease

被引:28
作者
Meijer, E. [1 ]
Boertien, W. E. [1 ]
Zietse, R. [2 ]
Gansevoort, R. T. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands
[2] Erasmus MC, Dept Nephrol, Rotterdam, Netherlands
关键词
Vasopressin; Copeptin; Chronic kidney disease; Autosomal dominant polycystic kidney disease; Albuminuria; Proteinuria; Glomerular filtration rate; RENAL CONCENTRATING CAPACITY; GLOMERULAR-FILTRATION-RATE; RENIN-ANGIOTENSIN SYSTEM; RECEPTOR ANTAGONISTS; DIABETES-MELLITUS; ANTIDIURETIC ACTION; PLASMA VASOPRESSIN; SURROGATE MARKER; BRATTLEBORO RATS; SODIUM-EXCRETION;
D O I
10.1159/000326902
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The antidiuretic hormone vasopressin is crucial for regulating free water clearance in normal physiology. However, it has also been hypothesized that vasopressin has deleterious effects on the kidney. Vasopressin is elevated in animals and patients with chronic kidney disease. Suppression of vasopressin activity reduces proteinuria, renal hypertrophy, glomerulosclerosis and tubulointerstitial fibrosis in animal models. The potential detrimental influence of vasopressin is probably mediated by its effects on mesangial cell proliferation, renin secretion, renal hemodynamics, and blood pressure. In this review, we discuss the increasing body of evidence pointing towards the contribution of vasopressin to chronic kidney disease progression in general and to autosomal dominant polycystic kidney disease in particular. These data allude to the possibility that interventions directed at lowering vasopressin activity, for example by the administration of vasopressin receptor antagonists or by drinking more water, may be beneficial in chronic kidney disease. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:235 / 244
页数:10
相关论文
共 50 条
  • [21] Kidney Function and Plasma Copeptin Levels in Healthy Kidney Donors and Autosomal Dominant Polycystic Kidney Disease Patients
    Zittema, Debbie
    van den Berg, Else
    Meijer, Esther
    Boertien, Wendy E.
    Kobold, Anneke C. Muller
    Franssen, Casper F. M.
    de Jong, Paul E.
    Bakker, Stephan J. L.
    Navis, Gerjan
    Gansevoort, Ron T.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (09): : 1553 - 1562
  • [22] Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease
    Boertien, Wendy E.
    Meijer, Esther
    de Jong, Paul E.
    Bakker, Stephan J. L.
    Czerwiec, Frank S.
    Struck, Joachim
    Oberdhan, Dorothee
    Shoaf, Susan E.
    Krasa, Holly B.
    Gansevoort, Ron T.
    KIDNEY INTERNATIONAL, 2013, 84 (06) : 1278 - 1286
  • [23] Autosomal dominant polycystic kidney disease: Is the treatment for tomorrow?
    Cornec-Le Gall, Emilie
    Le Meur, Yannick
    NEPHROLOGIE & THERAPEUTIQUE, 2014, 10 (06): : 433 - 440
  • [24] Recognizing and treating autosomal dominant polycystic kidney disease
    Uko, Chigozie G.
    NURSE PRACTITIONER, 2020, 45 (11) : 41 - 47
  • [25] Proteinuria in children with autosomal dominant polycystic kidney disease
    Seeman, Tomas
    Pohl, Michael
    John, Ulrike
    MINERVA PEDIATRICA, 2018, 70 (05) : 413 - 417
  • [26] Autosomal dominant polycystic kidney disease in young adults
    Martinez, Victor
    Furlano, Monica
    Sans, Laia
    Pulido, Lissett
    Garcia, Rebeca
    Vanessa Perez-Gomez, Maria
    Sanchez-Rodriguez, Jinny
    Blasco, Miquel
    Castro-Alonso, Cristina
    Fernandez-Fresnedo, Gema
    Roberto Robles, Nicolas
    Pau Valenzuela, Maria
    Naranjo, Javier
    Martin, Nadia
    Pilco, Melissa
    Agraz-Pamplona, Irene
    David Gonzalez-Rodriguez, Juan
    Panizo, Nayara
    Fraga, Gloria
    Fernandez, Loreto
    Teresa Lopez, Maria
    Dall'Anese, Cecilia
    Ortiz, Alberto
    Torra, Roser
    Marcas, Luis
    Rius, Asuncion
    Tomas, Patricia
    Garcia, Leonor
    Luna, Enrique
    Adoracion Martin, Maria
    Inigo, Pablo
    Martins, Judith
    Ramos, Fernanda
    Garcia, Rosa
    del Rio Garcia, Laura
    del Carmen Merino, Maria
    Jose Fernandez-Reyes, M.
    Madariaga, Leire
    Canal, Cristina
    Maria Martinez, Ana
    Echarri, Rocio
    Bouarich, Hanane
    Cabezas, Antonio
    CLINICAL KIDNEY JOURNAL, 2023, 16 (06) : 985 - 995
  • [27] Autosomal dominant polycystic kidney disease: updated perspectives
    Rastogi, Anjay
    Ameen, Khalid Mohammed
    Al-Baghdadi, Maha
    Shaffer, Kelly
    Nobakht, Niloofar
    Kamgar, Mohammad
    Lerma, Edgar, V
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 1041 - 1052
  • [28] Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function
    Boertien, Wendy E.
    Meijer, Esther
    de Jong, Paul E.
    ter Horst, Gert J.
    Renken, Remco J.
    van der Jagt, Eric J.
    Kappert, Peter
    Ouyang, John
    Engels, Gerwin E.
    van Oeveren, Willem
    Struck, Joachim
    Czerwiec, Frank S.
    Oberdhan, Dorothee
    Krasa, Holly B.
    Gansevoort, Ron T.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (06) : 833 - 841
  • [29] An update on tolvaptan for autosomal dominant polycystic kidney disease
    Poch, E.
    Rodas, L.
    Blasco, M.
    Molina, A.
    Quintana, L.
    DRUGS OF TODAY, 2018, 54 (09) : 519 - 533
  • [30] Autosomal Dominant Polycystic Kidney Disease: Is There a Role for Autophagy?
    Ponticelli, Claudio
    Moroni, Gabriella
    Reggiani, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)